Clinical trial
A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.
NCT07036250 is registered in ClinicalTrials.gov with Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.
- Lead sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- July 3, 2025
- Completion date
- December 31, 2029
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukaemia